

Elenco delle pubblicazioni censite da Medline, in inglese

- Rinott R, Torresani M, **Bertulli R**, Goldsteen A, Casali P, Carmeli B, Slonim N. [Automatic Detection of Inconsistencies between Free Text and Coded Data in Sarcoma Discharge Letters](#). *Stud Health Technol Inform*. 2012;180:661-6.
- Ferrari A, **Bertulli R**. [At the crossroads of molecular biology, pathology and the clinic](#). *Expert Rev Anticancer Ther*. 2012 Jun;12(6):725-8.
- Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, Comandone A, **Bertulli R**, Bisogno G, Palmerini E, Alberghini M, Parafioriti A, Linari A, Picci P, Bacci G. [Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1](#). *J Clin Oncol*. 2012 Jun 10;30(17):2112-8.
- Orsenigo M, Brich S, Riva C, Conca E, **Bertulli R**, Dileo P, Gronchi A, Casali PG, Pierotti MA, Tamborini E, Pilotti S. [Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors](#). *Anal Quant Cytol Histol*. 2010 Aug;32(4):225-33.
- Gronchi A, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, **Bertulli R**, Fiore M, Casali PG. [Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution](#). *Ann Oncol*. 2011 Jul;22(7):1675-81.
- Perrone F, Jocolle G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, **Bertulli R**, Pierotti MA, Zaffaroni N, Pilotti S. [Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma](#). *Eur J Cancer*. 2010 Oct;46(15):2837-48.
- Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, **Bertulli R**, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG. **High-grade soft-tissue sarcomas: tumor response assessment. Pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria**. *Radiology* 2009; 251: 447-456.
- Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, **Bertulli R**, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reychardt P. **A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors**. *Clin Cancer Res* 2009; 15:5910-6.
- Baratti D, Pennacchioli E, Casali PG, **Bertulli R**, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A. **Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution**. *Ann Surg Oncol* 2007; 14: 3542-51.
- Mannavola D, Coco P, Vannucchi G, **Bertulli R**, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. **A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake**. *J Clin Endocrinol Metab* 2007; 92: 3531-4.
- Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, **Bertulli R**, Carbone A, Pierotti MA, Tamborini E, Pilotti S. **c-Kit/PDGFRα gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors**. *Clin Cancer Res* 2007; 13: 2369-77.
- Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, **Bertulli R**, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG. **Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma**. *Eur J Cancer* 2006; 42: 1484-90.
- Fiore M, Casali PG, Miceli R, Mariani L, **Bertulli R**, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A. **Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity**. *Ann Surg Oncol* 2006;13: 110-7.
- Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciort R, Hogendoorn PC, Brown M, **Bertulli R**, Judson IR. **Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-italian sarcoma group-australasian gastrointestinal trials group study**. *J Clin Oncol* 2005; 23: 5795-804.
- Casali PG, **Bertulli R**, Fumagalli E, Coco P, Grosso F, Stacchiotti S. **Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors**. *J Chemother*. 2004;16 Suppl 4: 55-8.

- Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, **Bertulli R**, Collini P, Lozza L, Olmi P, Rosai J. **Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution.** *J Clin Oncol* 2005; 23: 96-104
- Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, **Bertulli R**, Judson I. **Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.** *Lancet* 2004; 364: 1127-34
- Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, **Bertulli R**, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. **Imatinib mesylate in chordoma.** *Cancer*. 2004; 101: 2086-97
- Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, **Bertulli R**, Olmi P, Casali PG. **Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.** *Cancer* 2004; 101: 627-34
- Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, **Bertulli R**, Colecchia M, Casali PG, Pierotti MA, Pilotti S. **A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.** *Gastroenterology* 2004; 127: 294-9
- Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, **Bertulli R**, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J. **Retroperitoneal soft tissue sarcomas. Patterns of recurrence in 167 patients treated at a single institution.** *Cancer* 2004; 100: 2448-2455
- Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, **Bertulli R**, Casali PG, Pierotti MA, Pilotti S. **Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.** *Clin Cancer Res* 2004; 10: 938-43.
- Ferrari A, Dileo P, Casanova M, **Bertulli R**, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG. **Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.** *Cancer* 2003; 98: 571-80
- Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, **Bertulli R**, Kusamura S. **Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.** *J Surg Oncol* 2003; 83: 147-53
- Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, **Bertulli R**, Fiore M, Olmi P, Santinami M, Rosai J. **Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.** *J Clin Oncol* 2003; 21:1390-7
- Azzarelli A, Gronchi A, **Bertulli R**, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG. **Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.** *Cancer* 2001; 92: 1259-64
- Collini P, Sampietro G, **Bertulli R**, Casali PG, Luksch R, Mezzelani A, Sozzi G, Pilotti S. **Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies** [letter to the Editor]. *Am J Surg Pathol* 2001; 25: 273-274
- Casali P, Pastorino U, Azzarelli A, **Bertulli R**, Zucchinelli P, Devizzi L, Santoro A. **Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.** *Cancer Chemoth Pharm* 1993; 31 Suppl 2: S228-32.
- Bretti S, Berruti A, Dogliotti L, castagneto B, **Bertulli R**, Spadaro P, Toscano G, Astorre P, verusio C, Lionetto R, Bruzzi P, Santoro A. **Combined epirubicin and interleukin-2 in the treatment of malignant mesothelioma: a multi center phase II study of the Italian Group on Rare Tumors.** *Tumori* 1998;84: 558-61.
- Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, **Bertulli R**, Balzarotti M, Rocca A, Lombardi F, Ferreri AJ, et al. **Combined modality treatment for primary gastrointestinal non-Hodgkin lymphoma: the Milan cancer Institute experience.** *Ann Oncol* 1993, 4: 831-7.